Elixirgen Scientific, Inc., a biotechnology company focused on advancing drug discovery and revolutionizing cell therapy through iPSC technology, has been accredited for ISO 9001:2015 certification, an internationally recognized standard that ensures a company’s products and services meet the needs of customers through an effective Quality Management System.
 
This achievement highlights Elixirgen Scientific’s on-going efforts in quality process enhancement across all operations, effective risk management, continuous improvement, and adherence with strict regulatory requirements.
 
The ISO 9001:2015 certification ensures that their iPSC-derived cells and services are developed and delivered under the highest standards of quality management, significantly enhancing their reliability and efficacy for advanced research and therapeutic applications.
 
“Today’s achievement is a significant milestone for us and a testament to our team’s relentless pursuit of excellence in iPSC technology and quality management. It reinforces our commitment to leading the way in scientific innovation, backed by the highest standards of quality,” remarks Dr. Keiki Sugimoto, CEO of Elixirgen Scientific.
 
For clients, this certification ensures that Elixirgen Scientific’s quality management system, manufacturing processes, and customer service consistently meet ISO’s internationally recognized standards. This achievement enhances their product and service quality, boosts customer satisfaction, and optimizes their business processes.